{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:05:06Z","timestamp":1791068706792,"version":"4.1.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>\n                    Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most effective type and dose of statin in this population. We sought to determine the impact of statin type and dose upon fibrosis progression and HCC in patients with HCV. Using the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) database, we identified all subjects initiated on HCV antibody (anti\u2010HCV) therapy from 2001 to 2014, and all incident cases of cirrhosis and HCC. Statin use was measured using cumulative defined daily dose (cDDD). Multivariable Cox's proportional hazard regression models were used to examine the relationship between statin use and development of cirrhosis and HCC. Among 9,135 eligible subjects, 1,649 developed cirrhosis and 239 developed incident HCC. Statin use was associated with a 44% reduction in development of cirrhosis (adjusted hazard ratio [HR]: 0.6; 95% confidence interval [CI]: 0.53, 0.68). The adjusted HRs (95% CI) of fibrosis progression with statin cDDD 28\u201089, 89\u2010180, and &gt;180 were 0.74 (0.59, 0.93), 0.71 (0.59, 0.88), and 0.6 (0.53, 0.68), respectively. Mean change in FIB\u20104 score with atorvastatin (n = 944) and fluvastatin (n = 34) was \u20100.17 and \u20100.13, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.04), after adjustment for baseline FIB\u20104 score and established predictors of cirrhosis. Statin use was also associated with a 49% reduction in incident HCC (adjusted HR: 0.51; 95% CI: 0.36, 0.72). A similar dose\u2010response relationship was observed.\n                    <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                    In patients with chronic HCV, statin use was associated with a dose\u2010dependent reduction in incident cirrhosis and HCC. Atorvastatin and fluvastatin were associated with the most significant antifibrotic effects, compared with other statins. (H\n                    <jats:sc>epatology<\/jats:sc>\n                    2016;64:47\u201357)\n                  <\/jats:p>","DOI":"10.1002\/hep.28506","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T19:18:21Z","timestamp":1455823101000},"page":"47-57","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":170,"title":["Atorvastatin and fluvastatin are associated with dose\u2010dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES"],"prefix":"10.1097","volume":"64","author":[{"given":"Tracey G.","family":"Simon","sequence":"first","affiliation":[{"name":"Liver Center, Gastrointestinal Division, Department of Medicine,Massachusetts General Hospital,Boston,MA"},{"name":"Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Bonilla","sequence":"additional","affiliation":[{"name":"Diablo Infectious Diseases,Castro Valley,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yan","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, Doha,Qatar and New York,NY"},{"name":"University of Pittsburgh School of Medicine,Pittsburgh,PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[{"name":"Liver Center, Gastrointestinal Division, Department of Medicine,Massachusetts General Hospital,Boston,MA"},{"name":"Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel A.","family":"Butt","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, Doha,Qatar and New York,NY"},{"name":"University of Pittsburgh School of Medicine,Pittsburgh,PA"},{"name":"Hamad Healthcare Quality Institute and Hamad Medical Corporation,Doha,Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,3,25]]},"reference":[{"key":"hep28506-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","year":"2006","journal-title":"Ann Intern Med"},{"key":"hep28506-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C","volume":"9","year":"2005","journal-title":"Clin Liver Dis"},{"key":"hep28506-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all\u2010cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","year":"2012","journal-title":"JAMA"},{"key":"hep28506-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"hep28506-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/597039","article-title":"Antimicrobial and immunomodulatory attributes of statins: relevance in solid\u2010organ transplant recipients","volume":"48","year":"2009","journal-title":"Clin Infect Dis"},{"key":"hep28506-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1158\/0008-5472.CAN-04-0866","article-title":"Blocking the Raf\/MEK\/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin\u2010induced apoptosis","volume":"64","year":"2004","journal-title":"Cancer Res"},{"key":"hep28506-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1073\/pnas.96.14.7797","article-title":"Lovastatin\u2010mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl\u2010CoA reductase","volume":"96","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep28506-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ejca.2008.06.025","article-title":"Statins and cancer: a systematic review and meta\u2010analysis","volume":"44","year":"2008","journal-title":"Eur J Cancer"},{"key":"hep28506-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial\u2010mesenchymal transition and its implications for fibrosis","volume":"112","year":"2003","journal-title":"J Clin Invest"},{"key":"hep28506-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3181\/0707-MR-190","article-title":"Mechanisms of fibrogenesis","volume":"233","year":"2008","journal-title":"Exp Biol Med"},{"key":"hep28506-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","year":"2008","journal-title":"Lancet"},{"issue":"Suppl 2","key":"hep28506-bib-0012-20241017","first-page":"65","article-title":"What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis","volume":"27","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"hep28506-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3748\/wjg.v19.i2.241","article-title":"Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats","volume":"19","year":"2013","journal-title":"World J Gastroenterol"},{"key":"hep28506-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bpg.2011.02.011","article-title":"Anti\u2010fibrogenic strategies and the regression of fibrosis","volume":"25","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"hep28506-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nrc1751","article-title":"Statins and cancer prevention","volume":"5","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"hep28506-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hep.24397","article-title":"Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER\u2010Medicare database","volume":"54","year":"2011","journal-title":"Hepatology"},{"key":"hep28506-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1200\/JCO.2006.06.3560","article-title":"Statins and cancer risk: a literature\u2010based meta\u2010analysis and meta\u2010regression analysis of 35 randomized controlled trials","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"hep28506-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta\u2010analysis","volume":"144","year":"2013","journal-title":"Gastroenterology"},{"key":"hep28506-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","year":"2010","journal-title":"J Hepatol"},{"key":"hep28506-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1872-034X.2010.00769.x","article-title":"Pitavastatin inhibits hepatic steatosis and fibrosis in non\u2010alcoholic steatohepatitis model rats","volume":"41","year":"2011","journal-title":"Hepatol Res"},{"key":"hep28506-bib-0021-20241017","first-page":"76","article-title":"Caspase\u20107 is activated during lovastatin\u2010induced apoptosis of the prostate cancer cell line LNCaP","volume":"58","year":"1998","journal-title":"Cancer Res"},{"key":"hep28506-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","article-title":"Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep28506-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.2012.44.6831","article-title":"Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"hep28506-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep.27835","article-title":"Effect of addition of statins to antiviral therapy in hepatitis C virus\u2010infected persons: results from ERCHIVES","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep28506-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.21232","article-title":"Different anti\u2010HCV profiles of statins and their potential for combination therapy with interferon","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep28506-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1572-0241.2008.01876.x","article-title":"Fluvastatin inhibits hepatitis C replication in humans","volume":"103","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"hep28506-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"e96533","DOI":"10.1371\/journal.pone.0096533","article-title":"Matrix conditions and KLF2\u2010dependent induction of heme oxygenase\u20101 modulate inhibition of HCV replication by fluvastatin","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"hep28506-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","article-title":"Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep28506-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamainternmed.2014.6502","article-title":"Liver fibrosis progression in hepatitis C virus infection after seroconversion","volume":"175","year":"2015","journal-title":"JAMA Intern Med"},{"key":"hep28506-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/j.1572-0241.2006.00754.x","article-title":"Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office","volume":"101","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"hep28506-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.21662","article-title":"Predictors of response of US veterans to treatment for the hepatitis C virus","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"hep28506-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(03)00187-9","article-title":"Twelve weeks of follow\u2010up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C","volume":"39","year":"2003","journal-title":"J Hepatol"},{"key":"hep28506-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2893.2012.01635.x","article-title":"Noninvasive estimation of fibrosis progression overtime using the FIB\u20104 index in chronic hepatitis C","volume":"20","year":"2013","journal-title":"J Viral Hepat"},{"key":"hep28506-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.0409834102","article-title":"Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids","volume":"102","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep28506-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1038\/onc.2012.6","article-title":"Targeting tumor cell metabolism with statins","volume":"31","year":"2012","journal-title":"Oncogene"},{"key":"hep28506-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","year":"2015","journal-title":"Gut"},{"key":"hep28506-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1002\/cncr.24687","article-title":"Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link","volume":"115","year":"2009","journal-title":"Cancer"},{"key":"hep28506-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cgh.2008.02.012","article-title":"Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients","volume":"6","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep28506-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1478-3231.2009.02043.x","article-title":"Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus","volume":"29","year":"2009","journal-title":"Liver Int"},{"key":"hep28506-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/jvh.12085","article-title":"A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naive genotype 1 hepatitis C patients","volume":"20","year":"2013","journal-title":"J Viral Hepat"},{"key":"hep28506-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12876-015-0248-8","article-title":"Fluvastatin attenuates hepatic steatosis\u2010induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells","volume":"15","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"hep28506-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbrc.2011.12.091","article-title":"Statins inhibit expression of thioredoxin reductase 1 in rat and human liver and reduce tumour development","volume":"417","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"hep28506-bib-0044-20241017","first-page":"735","article-title":"Simvastatin inhibits cell growth and induces apoptosis and G0\/G1 cell cycle arrest in hepatic cancer cells","volume":"26","year":"2010","journal-title":"Int J Mol Med"},{"key":"hep28506-bib-0045-20241017","first-page":"1167","article-title":"Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria\u2010operated pathway","volume":"48","year":"2010","journal-title":"Indian J Exp Biol"},{"key":"hep28506-bib-0046-20241017","doi-asserted-by":"crossref","first-page":"e80304","DOI":"10.1371\/journal.pone.0080304","article-title":"Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin\u2010like kinase\u2010mediated mechanism","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"hep28506-bib-0047-20241017","first-page":"879","article-title":"Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK","volume":"38","year":"2011","journal-title":"Int J Oncol"},{"key":"hep28506-bib-0048-20241017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jnci\/djm286","article-title":"The association between statins and cancer incidence in a veterans population","volume":"100","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"hep28506-bib-0049-20241017","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"hep28506-bib-0050-20241017","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2010.01.022","article-title":"A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases","volume":"17","year":"2010","journal-title":"Cancer Cell"},{"key":"hep28506-bib-0051-20241017","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","year":"2012","journal-title":"Genes Dev"},{"key":"hep28506-bib-0052-20241017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cancergen.2015.03.008","article-title":"Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells","volume":"208","year":"2015","journal-title":"Cancer Genet"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28506","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201607000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:33:55Z","timestamp":1729193635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201607000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,25]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.28506","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726155359.793520441","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726155359.793545265","asserted-by":"object"}]},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,25]]},"assertion":[{"value":"2015-10-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}